Reports for APOTEX INC
Company Name
APOTEX INC
Shortage reports
Actual shortage:
220 (7%)
Anticipated shortage:
0 (0%)
Avoided shortage:
10 (0%)
Resolved:
3124 (93%)
3354
Discontinuation Reports
To be discontinued:
25 (7%)
Discontinued:
342 (93%)
Reversed:
0 (0%)
367
146 (4%)
70 (29%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-CARVEDILOL | 6.25MG | TABLET | Resolved | 2019-10-09 | 2020-09-21 | 95853 |
| APO-CARVEDILOL | 3.125MG | TABLET | Resolved | 2020-06-10 | 2020-09-21 | 117348 |
| APO-CEFACLOR | 250MG | CAPSULE | Actual shortage | 2017-08-13 | 2017-10-05 | 19036 |
| APO-CEFACLOR | 500MG | CAPSULE | Actual shortage | 2017-08-13 | 2017-10-05 | 19039 |
| APO-CEFACLOR | 125MG | POWDER | Actual shortage | 2017-08-13 | 2017-10-05 | 19066 |
| APO-CEFACLOR | 250MG | POWDER | Actual shortage | 2017-08-13 | 2017-10-05 | 19069 |
| APO-CEFACLOR | 375MG | POWDER | Actual shortage | 2017-08-13 | 2017-10-05 | 19072 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2019-07-12 | 2019-11-25 | 89155 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2024-07-25 | 2024-08-09 | 233706 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2024-09-12 | 2024-10-11 | 237372 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2024-11-14 | 2024-12-13 | 243086 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2023-04-21 | 2024-03-08 | 190008 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2017-04-17 | 2017-04-25 | 7102 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2022-11-20 | 2022-12-23 | 175327 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2025-01-16 | 2025-02-28 | 247862 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2021-07-23 | 2021-10-12 | 142973 |
| APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2021-06-11 | 2021-08-06 | 140772 |
| APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2021-09-17 | 2021-10-25 | 145822 |
| APO-CEFEPIME | 1G | POWDER FOR SOLUTION | Resolved | 2024-01-19 | 2024-02-09 | 216672 |
| APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2024-02-23 | 2024-03-01 | 220444 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BROMAZEPAM - TAB 1.5MG | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM - TAB 3MG | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM - TAB 6MG | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |